biochem 503 fall 2005 - university of...
TRANSCRIPT
1
Biochem 503 Fall 2005
Protein Tyr Phosphatases
David Brautigan
assigned reading:
Stoker (2005) J. Endocrin. 185:19-33
Protein Phosphotyrosyl Phosphatase
PubMed Items 282 - 284 of 284282:Swarup G, Cohen S, Garbers DL. Inhibition of membrane phosphotyrosyl-protein phosphatase activity byvanadate.Biochem Biophys Res Commun. 1982 Aug;107(3):1104-9. No abstract available. PMID: 6291515 [PubMed -indexed for MEDLINE]
283:Swarup G, Speeg KV Jr, Cohen S, Garbers DL. Phosphotyrosyl-protein phosphatase of TCRC-2 cells.J BiolChem. 1982 Jul 10;257(13):7298-301. PMID: 6282838 [PubMed - indexed for MEDLINE
284:Brautigan DL, Bornstein P, Gallis B. Phosphotyrosyl-protein phosphatase. Specific inhibition by Zn.J Biol Chem.1981 Jul 10;256(13):6519-22. PMID: 6165721 [PubMed - indexed for MEDLINE
History 1981-1982 First description of P-Tyr specific phosphohydrolyase
activity in cell membrane fractions. EGF-R as substrateSelective inhibition by Zn2+ or vanadate
1983-1986 Development of assays using P-Tyr proteins: histone, poly[Glu:Tyr], denatured BSA and lysozyme.Biochemical fractionations and properties of PTPs from various tissues and cell lines. Reaction with GFRs, requirement for SH; both membrane and cytosolic formssize of 35 kDa
2
1987-1988 purification of PTP from human placenta (Tonks and Fischer)
1988-1989 partial peptide sequence of PTP1B (Charbonneau, Tonks, Walsh & Fischer)
1990 demonstration of CD45 as a PTPase
Unexpected sequence similarity to existing protein CD-45CD45 already known as abundant lymphocyte surface antigen Nick Tonks
CSHL
PTP1B
CD45, aka LCA, B220
40% 33%
1990’s sequence and cloning of other PTPs
Jack Dixon at Purdue; U of Michigan; UCSD
showed Phospho-Cys intermediate in PTPsactive site sequence motif used to find distant relativesVHR viral PTP related to VH1 DSPYOP51 Yersina virulence genePTEN is a lipid phosphatase for PIP3
Ben Neel at Harvard Med. School
ER localization of PTP1Bcloning and properties of SH2-PTPsmotheaten mouse (SHP hypomorph)
3
1990’s 3D X-ray structures of PTPs - VH1, PTP1B, etc
PTP1B knockout mousecritical test of PTP as drug target for diabetes
David BarfordOxford England
Michel TremblayMcGill Univ., Montreal
Mark SaperUniv. of Michigan
Vanadate complex that mimics phospho-enzyme
Oxidation of Cys to cyclic
PTP Phosphatases in The Human Genome
Cell (2004) 117:699
transmembrane
cytoplasmic
assorted others
4
Protein Tyr Phosphatases (PTPs)A. Mechanism of action and Kinetics
1. specificity for P-Tyr, vs, P-Ser or P-Thra large (long, aromatic) sidechainP-Tyr is a high energy phosphoester, used as intermediate in
topoisomerasesunusual KM < 1 uM, implies special interactions - trapping mechanism
2. signature catalytic site sequence HCxxGxxRwith essential Cys SH group, and R residue
Catalytic Mechanism of Phosphoester Hydrolysis by PTPs
fastslow
pKa ~5.5
5
3. phospho-enzyme intermediate Cys-S-PO4a. vanadate mimics the transition state of phosphate
b. proton transfer to leaving group TyrOH by D181 is essential c. hydrolysis and product (PO4) release is rate-limiting, d. 1000 sec-1 reduced to 0.02 sec-1 by D181A mutation e. either Cys to Ser or Asp to Ala mutations make inactive PTP
4. reversible oxidation mechanism of Cys by H2O2forms cyclic cysteinyl-sulfenyl-amide, can be reduced by thiols
OH S OH CH2 CH2HN-CH-C-NH-CH-C-NH O O
ROS or H2O2
Cys-SH ------> Cys-SOH
6
B. Families of Tyr Phosphatases (PTPs)
1.Transmembrane PTPs - the prototype CD-45
a. common features (most)1. single TM helix to span membrane2. double PTP domain, with activity in N terminal (D1) domain3. large extracellular domains, related to cell-cell adhesion4. inhibited by dimerization - the 'wedge' hypothesis5. activators of src kinases by Tyr527 dephosphorylation
b. differences1. tissue and developmental expression2. substrate specificity, but few targets known
knockouts and trapping mutants3. inhibitors of active sites as pharmaceuticals
7
Cys-SH
Cys-SH
Cys-SH
Cys-SNHROS
active inactive
Regulation of Transmembrane PTPs by Oxidation of D2 Domains
8
2. Cytosolic PTPs, the prototype PTP1B
a. common features1. single PTP domain, plus targeting sequences2. specificity for P-Tyr vs. P-Ser3. Phospho-Cys-enzyme intermediate4. Substrate trap by conformational movement5. Oxidation-reduction control mechanism
b. differences1. tissue expression2. specificity for substrates3. Inhibition by small molecules
PTP catalytic domain
9
SHP2 phosphatase regulated by P-Tyr binding:either intrasteric or intermolecular
PTP
SH2
SH2PTP
SH2 SH2
P-Tyr P-Tyr
Y542
Y580
10
SHP2 phosphataseActivating mutationsin Noonan’s Syndrome
PTP
SH2
SH2
Split opento expose interface
3. Dual specificity Phosphatases, the prototype VH1
a. mechanism common with PTPs, i.e. Cys-Phosphatebut shallow active site to accommodate P-Ser/P-Thr
b. the MKPs, MAP kinase phosphatasesbinds to MAPK at site in N terminal domainand this activates the MKP C terminal catalytic domain
several members : CL100, MKP1, 2, 3, 4,
c. the cdc25 family of CDK phosphataseslow activity phosphatase with extreme specificitylarge inhibitory domain, activated by phosphorylationnot really a family member- it’s like Rhodanase(??)
11
Dual-specificity Phosphatase - MAPK PP-aseCatalytic domain
12
cdc25 - not really related to other PTPs
13
4. Other Cys-dependent Phosphatases - prototype PTEN
a. enzymes that share the catalytic site motif HCxxxRdiscovered by sequence searches
b. PTEN mutated in many human tumors.lipid phosphatase, removes P from PIP3 to reverse action of PI3Kresults in elevated PIP3 and activation of Akt/PKB - survival signal
c. Myotubularin a family of proteins, other PIP3 phosphatases
d. cdc14 phosphatase dephosphorylates Thr in CDK activation loop
e. Slingshot dephosphorylates cofilin at Ser3 to regulate actin
Overview of the PTP Superfamily of Phosphatases